Lyxumia is an injectable medicine for controlling blood sugar level that is generally designed for adults with type 2 diabetes with high sugar. It is a supplementary medicine to oral antidiabetic medicine such as metformin and pioglitazone, as well as basal insulin. Lyxumia contains the active substance lixisenatide, an incretin mimetic medicine that works by mimicking the actions of a hormone called glucagon-like peptide-1 (GLP-1) which help control blood glucose by stimulating the production of insulin and reducing the production of glucagon.

The use of Lyxumia was approved by the European Commission for commercial marketing only last 2013. Lyxumia is the first once-daily prandial GLP-1 receptor agonist for the managing glycemic control in adult patients with type 2 diabetes mellitus in combination with oral glucose-lowering medicinal products and / or basal insulin when these, together with diet and exercise. It must be noted that it does not provide adequate glycemic control.

It is important for diabetics to consult their doctors first before taking Lyxumia because it can potentially trigger allergic reactions to some individuals. Moreover, following are factors or conditions in which taking Lyxumia is not recommended:

• Diabetics with type 1 diabetes (diabetic ketoacidosis)
• Diabetics with inflammation of the pancreas (pancreatitis)
• Diabetics with gastroparesis
• Diabetics with severe kidney disease or are undergoing dialysis
• Diabetics taking a sulphonylurea or a basal insulin to avoid hypoglycaemia
• Diabetics taking other medicines such as antibiotics or stomach resistant tablets
• Diabetics experiencing dehydration due to vomiting, nausea and diarrhoea
• Diabetics suffering from heart problems
• Diabetics who are less than 18 years old
• Diabetics who are pregnant or are breast feeding

Related Posts:

• No Related Posts